MedTrace Logo

Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

NCT01426256 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2017-07-13

No results posted yet for this study

Summary

The purpose of this study is determine if high-dose vitamin D supplementation improves clinical outcomes related to lung function and immunity in patients with Cystic Fibrosis who are admitted to the hospital with an acute lung infection.

Conditions

Interventions

DIETARY_SUPPLEMENT

Cholecalciferol

Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Emory University

    lead OTHER

Principal Investigators

  • Vin Tangpricha, MD, PhD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2017-04-30
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426256 on ClinicalTrials.gov